

## Supplemental Digital Content 2. Table: STROBE Checklist

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Location in manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Title states design of study
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Introduction, paragraph 1-2
Objectives	3	State specific objectives, including any prespecified hypotheses	Introduction, final paragraph
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	Materials and Methods, paragraph Study Design, Setting, and Participants
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Materials and Methods, paragraph Study Design, Setting, and Participants
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Materials and Methods, paragraph Study Design, Setting, and Participants
		(b) For matched studies, give matching criteria and number of exposed and unexposed	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Materials and Methods, Data collection, Outcomes, and SARS-CoV-2 variants and population immunity paragraphs
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Materials and Methods, Data collection, Outcomes, and SARS-CoV-2 variants and population immunity paragraphs
Bias	9	Describe any efforts to address potential sources of bias	Materials and Methods, SARS-CoV-2 variants and population immunity, and Statistical Analysis paragraphs
Study size	10	Explain how the study size was arrived at	Supplemental Digital Content 4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Materials and Methods, Outcomes, SARS-CoV-2 variants and population immunity, and Statistical Analysis paragraphs
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Materials and Methods, Statistical Analysis paragraph
		(b) Describe any methods used to examine subgroups and interactions	Materials and Methods, Statistical Analysis paragraph
		(c) Explain how missing data were addressed	Materials and Methods, Statistical Analysis paragraph
		(d) If applicable, explain how loss to follow-up was addressed	Not applicable
		(e) Describe any sensitivity analyses	Materials and Methods, Statistical Analysis paragraph
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Results, paragraph Clinical cohort characteristics

		(b) Give reasons for non-participation at each stage	Results, paragraph Clinical cohort characteristics
		(c) Consider use of a flow diagram	Supplemental Digital Content 4
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Results, paragraph Clinical cohort characteristics, and supplementary appendix: eTable 1
		(b) Indicate number of participants with missing data for each variable of interest	Supplemental Digital Content 5
		(c) Summarise follow-up time (eg, average and total amount)	Not applicable
Outcome data	15*	Report numbers of outcome events or summary measures over time	Results, Incidence rate during phases of the pandemic, and Risk factors for severe disease paragraphs
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Results, Incidence rate during phases of the pandemic, and Risk factors for severe disease paragraphs
		(b) Report category boundaries when continuous variables were categorized	Results, Incidence rate during phases of the pandemic, and Risk factors for severe disease paragraphs
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not relevant
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Results, Clinical cohort characteristics, Incidence rate during phases of the pandemic and Dynamics of disease severity over time paragraphs
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	Discussion, paragraph 2-5
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Discussion, paragraph 6
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Discussion, paragraph 7
Generalisability	21	Discuss the generalisability (external validity) of the study results	Discussion, paragraph 7
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Title Page and Acknowledgments

\*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.